Clinical Trial Update: Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection [NA]

View source ↗

Summary

This trial update describes evaluating adjuvant therapy with sintilimab plus lenvatinib for hepatocellular carcinoma with VETC after liver resection; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Wan-Guang Zhang | Conditions: Hepatocellular Carcinoma (HCC) | NA | Status: NOT_YET_RECRUITING